Cargando…

Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B

BACKGROUND/AIMS: Little is known about the effect of early flares on response during first-line tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB). The aim of this study was to investigate the incidence and outcome of early alanine aminotransferase (ALT) flare in treatment-n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Hee Yeon, Lee, Han Ah, Ko, Soon Young, Wang, Joon Ho, Kim, Jeong Han, Choe, Won Hyeok, Kwon, So Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497666/ https://www.ncbi.nlm.nih.gov/pubmed/28479588 http://dx.doi.org/10.3350/cmh.2016.0067

Ejemplares similares

Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B
por: Choe, Jae Young, et al.
Publicado: (2017)

Virologic Response and Safety of Tenofovir Versus Entecavir in Treatment-Naïve Chronic Hepatitis B patients
por: Yu, Hyung Min, et al.
Publicado: (2015)

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
por: Kim, Jeong Han, et al.
Publicado: (2016)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations
por: Choe, Won Hyeok, et al.
Publicado: (2019)

A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B
por: Lee, Kyung Jae, et al.
Publicado: (2018)

Reversible splenial lesion on the corpus callosum in nonfulminant hepatitis A presenting as encephalopathy
por: Ko, Soon Young, et al.
Publicado: (2014)

Chronic Hepatitis C: Acute Exacerbation and Alanine Aminotransferase Flare
por: Kanda, Tatsuo, et al.
Publicado: (2023)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort
por: Ahn, Sung Soo, et al.
Publicado: (2014)

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
por: Kim, Jeong Han, et al.
Publicado: (2014)

Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure
por: Lee, Cho I, et al.
Publicado: (2014)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
por: Kim, Jeong Han, et al.
Publicado: (2013)

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
por: Park, Chan Ho, et al.
Publicado: (2016)

Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
por: Yoon, Kun Ho, et al.
Publicado: (2011)

Noninvasive Fibrosis Marker Can Predict Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation
por: Chung, Hyun Ah, et al.
Publicado: (2016)

HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data
por: Kim, Jeong Han, et al.
Publicado: (2013)

Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients
por: Kim, Byung Kook, et al.
Publicado: (2013)

A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B
por: Jindal, Ankur, et al.
Publicado: (2019)

Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
por: Lee, Soon Kyu, et al.
Publicado: (2017)

A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients
por: Kim, Hyung Joon, et al.
Publicado: (2022)

Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2
por: Kim, Ji-Eun, et al.
Publicado: (2017)

Characterization of T cell immunity in chronic hepatitis B virus-infected mothers with postpartum alanine transaminase flare
por: Huang, Meiting, et al.
Publicado: (2021)

Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea
por: Choi, HeeKyoung, et al.
Publicado: (2021)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
por: Ko, Soon Young, et al.
Publicado: (2018)

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
por: Lee, Sung Won, et al.
Publicado: (2020)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Effectiveness of Tenofovir Alafenamide in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase and Positive Hepatitis B Virus DNA
por: Gao, Wen-Kang, et al.
Publicado: (2022)

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients
por: Lee, Heon Ju, et al.
Publicado: (2018)

What Is the Optimal Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients?: The Practical Evidence of Antidiabetic Monotherapy Study
por: Choi, Ji Hun, et al.
Publicado: (2011)

Clinical features of acute viral hepatitis B in Korea: a multi-center study
por: Choi, Hye Jin, et al.
Publicado: (2011)

Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients
por: Park, Ji Won, et al.
Publicado: (2017)

Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis
por: Chen, Ling, et al.
Publicado: (2016)

Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis
por: Lee, Young-Sun, et al.
Publicado: (2021)

The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites
por: Kim, Jun Jae, et al.
Publicado: (2014)

Baracle(®) vs Baraclude(®) for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety
por: Kim, Do Young, et al.
Publicado: (2017)

Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
por: Kim, Young Min, et al.
Publicado: (2018)

Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
por: Lee, Yun Bin, et al.
Publicado: (2017)

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
por: Liang, Xieer, et al.
Publicado: (2022)

Observational study on the response of tenofovir monotherapy versus tenofovir plus telbivudine dual therapy in patients with hepatitis B virus related acute on chronic liver failure
por: Manik, Abul H, et al.
Publicado: (2021)

Potential prognostic factors for solitary hepatocellular carcinoma ≤ 5 cm after transarterial chemoembolization
por: Ko, Soon Young, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3h6jl7ihj6kua66og8tqsrr2hg